Formulary Search Results for: CALCIUM AND VITAMIN D
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indications:
- Lung cancer:
- As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (programmed cell death ligand 1) on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.
- In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
- As monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
- Biliary tract cancer: In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.
- Endometrial cancer: In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:
- durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
- Liver cancer: In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
- Bladder cancer: In combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by durvalumab as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with resectable muscle invasive bladder cancer (MIBC).
12.2.4 Biologic treatments for use in chronic rhinosinusitis with nasal polyps - View Category
Restrictions:
Restricted to specialist use as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control, and who have had one or more prior surgery for chronic rhinosinusitis with nasal polyps and have a SNOT-22 score of 50 or higher.
3.12 Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies - View Category
Restrictions:
Restricted to specialist use for the treatment of the following indication:
- Treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
5.3.1.5 Other HIV combination preparations - View Category
Restrictions:
Restricted to use by HIV specialists.
Prescribing Notes:
Please note: Only this combination preparation containing cobicistat is included in the Formulary. Cobicistat tablets as a separate preparation (Tybost®) are not recommended for use by the Scottish Medicines Consortium and are non-Formulary.
5.3.1.5 Other HIV combination preparations - View Category
Restrictions:
The use for the treatment of HIV-1 infection in treatment naive adults, or treatment experienced adults without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load ≤100,000 HIV-1 RNA copies/mL, is restricted to HIV specialists only.
15.1.1 Intravenous anaesthetics - View Category
Restrictions:
Use for sedation in adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale [RASS] 0 to -3) is restricted to specialist use in accordance with local protocol.
Prescribing Notes:
The following indications are not recommended for use by the SMC and are non-Formulary:
- Sedation of non-intubated adults prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.
15.1.8 Drugs for malignant hyperthermia - View Category
15.1.4.2 Non-opioid analgesics - View Category
9.1.1.2 Parenteral iron - View Category
Restrictions:
The treatment of iron deficiency anaemia (diagnosis based on laboratory tests) when oral iron preparations are ineffective or cannot be used is restricted to specialist use.
Prescribing Notes:
These preparations are more expensive than some other IV iron preparations. Use in patients on haemodialysis or use as a bolus injection was not recommended by SMC and remains non-Formulary.
9.1.4 Drugs used in platelet disorders - View Category
Restrictions:
Restricted to specialist use for the following indications:
- The treatment of severe thrombocytopenia in adults with chronic liver disease who are scheduled to undergo an invasive procedure.
- The treatment of primary chronic thrombocytopenia (ITP) refractory to other treatments (e.g. corticosteroids or immunoglobulins) where patients have severe symptomatic ITP or a high risk of bleeding in accordance with local protocol.